Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

With weight loss drugs like metformin and Ozempic gaining popularity, it's essential to understand how they compare. So we ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

Average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 -- the lowest average recorded in a ...

Atrial fibrillation (AF) is the most common abnormal heart rhythm affecting 6 million people in the USA and can cause strokes and heart failure. Conventional treatments are successful but may need to ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

.Semaglutide: Novo Nordisk Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for ...

After battling with her own GI issues, Krystyna Houser took to innovating the Elemental Diet, a medical food which also ...